Table 3.

Factors associated with incremental blood glucose levels using linear mixed effect model (N = 444 hypoglycemic episodes across 398 infants)

Factors	Blood glucose increment (mg/dL)
	Coefficient (95% confidence interval)	p*
Intercept	27 (23, 30)	< 0.001*
50% oral dextrose solution	8.38 (4.5, 12.0)	< 0.001*
Postnatal age in the placebo group (hour)	0.17 (−0.27. 0.60)	0.455
Recruitment site (Bhumibol Adulyadej vs. Siriraj)	−1.48 (−5.6, 2.6)	0.477
Gestational age, centered (weeks)	1.04 (−0.11, 2.20)	0.075
Birthweight, centered (every 100-g increment)	−0.00 (−0.4, 0.4)	0.998
Small-for-gestational age	−5.77 (−11.00, −0.59)	0.029*
Large-for-gestational age	−7.06 (−14.00, −0.31)	0.040*
Infant of diabetic mother	−0.65 (−4.1, 2.8)	0.710
Postnatal age-solution interaction	−0.88 (−1.5, −0.24)	0.007*

Random effects: Residual variance (σ²) = 190.80; random intercept variance (τ00) = 33.89; ICC = 0.15; marginal R² = 0.068; conditional R² = 0.208; RMSE = 12.6 mg/dL

Linear mixed-effects model (dependent variable: blood glucose increments following administration of allocated solution), with a random intercept per infant. Small-for-gestational age (SGA) was compared against non-SGA infants; large-for-gestational age (LGA) was compared against non-LGA infants; infant of diabetic mother was compared against infants of non-diabetic mothers. Two post-treatment BG measurements were not performed in the placebo group after the 2nd and 3rd doses. *p-value less than 0.05 is considered statistically significant